TAVIST Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tavist, and when can generic versions of Tavist launch?
Tavist is a drug marketed by Novartis and Haleon Us Holdings and is included in four NDAs.
The generic ingredient in TAVIST is acetaminophen; clemastine fumarate; pseudoephedrine hydrochloride. There are sixty-six drug master file entries for this compound. Additional details are available on the acetaminophen; clemastine fumarate; pseudoephedrine hydrochloride profile page.
Summary for TAVIST
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 86 |
Clinical Trials: | 1 |
Patent Applications: | 3,376 |
Formulation / Manufacturing: | see details |
DailyMed Link: | TAVIST at DailyMed |
Recent Clinical Trials for TAVIST
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of California, San Francisco | Phase 2 |
Moorfields Eye Hospital NHS Foundation Trust | Phase 2 |